Healthcare
Rising BioSciences, Inc.(RBII)
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- —
- Revenue Growth
- +377.8%
- EPS Growth
- +100.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rising BioSciences, Inc. (RBII) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +377.8%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue +377.8%, EPS +100.0%, free cash flow +50.0% with operating margin 36.3% and ROIC -851.8%. Valuation is more restrained than many high-expectation growth names at P/E 0.2 and price/sales 0.0. Stock Foundry combines RBII price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+377.8% vs +7.6% peer median
Operating Margin
Above sector median
+36.3% vs +19.4% peer median
P/E
Below sector median
0.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +377.8% and EPS at +100.0%, with operating margin around 36.3%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RBII
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RBII Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RBII and SPY.
Company Overview
Rising BioSciences, Inc.
Other OTC
Rising BioSciences, Inc. develops and manufactures topical and oral pharmaceutical products, including medical marijuana products. The company is based in Sheridan, Wyoming.
- Leadership
- Arthur Hall
- IPO Date
- Apr 28, 2017
- Street Address
- 30 North Gould Street
- Mailing
- Sheridan, AR
- Region
- Sheridan, AR, US
- Reporting Currency
- USD
- Investor Line
- +1 330 333 4633
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 0.2
- EV/EBITDA
- 6.6
- Price/Sales
- 0.0
- Price/Book
- —
Growth
- Revenue
- +377.8%
- EPS
- +100.0%
- Free Cash Flow
- +50.0%
Profitability
- Gross Margin
- 57.3%
- Operating Margin
- 36.3%
- Net Margin
- 6.4%
- ROE
- -4.4%
- ROIC
- -851.8%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.